Below are the 4 most recent journal entries recorded in lowellbrowni102's InsaneJournal:

Wednesday, February 22nd, 2012
11:36 am	All about Capecitabine, Velcade, Pazopanib inhibitors Capecitabine is an orally administered prodrug of 5-fluorouracil (5-FU). It is currently approved for dealing metastatic breast cancer refractory to anthracyclines and paclitaxel, together with for first-line treatment of metastatic colorectal cancer. The drug belongs to your new and rapidly expanding class of therapeutics, manufactured for oral treatment of cancer. Oral treatment comes with several advantages over as i. v. treatment, especially in patients with incurable melanoma. It can lead to prolonged exposure of tumor cells on the antineoplastic effects of anticancer substances, mimicking the more heavy continuous i. v. infusions; it is more convenient for people, of whom >80% would prefer oral to i. v. treatment; and it may very well be less expensive, considering fees saved in drug administration An additional advantage, which makes capecitabine Capecitabine inhibition,Velcade inhibitor,Pazopanib inhibition an attractive compound, is its assumed concentrating on of tumor tissue. The parent drug is first converted to 5′-deoxy-5-fluorocytidine (5′-DFCR) through the enzyme carboxylesterase, which is present predominantly in the liver. 5′-DFCR is then changed into 5′-deoxy-5-fluorouridine (5′-DFUR) by way of the enzyme cytidine deaminase, which is more widely distributed including the liver and various cancerous growth tissues. Finally, 5′-DFUR is converted to 5-FU by thymidine phosphorylase (TP). TP is identical to your angiogenic agent ‘platelet derived endothelial cell growth factor’ (PD-ECGF). Expression of TP is usually increased in tumor tissue weighed against normal tissue. The proposed accumulation associated with 5-FU in tumors by metabolic targeting has been confirmed by measurement associated with 5-FU concentrations in colorectal cancer tissue weighed against adjacent normal tissue. Targeting of tumor flesh by capecitabine may result in a favorable balance of treatment efficacy and toxicity. Cardiotoxicity, a rare but potentially severe toxicity of fluoropyrimidines, hasn't been reported for capecitabine to date. Here we report a patient without evidence of cardiomyopathy or coronary heart disease, who developed heart ischemia with severe angina after oral administration of capecitabine. This observation suggests the demand for caution when treating patients considered susceptible to fluoropyrimidine-associated cardiac toxicity. To evaluate the efficacy and toxicity of capecitabine maintenance therapy within metastatic colorectal cancer(mCRC)patients. Options: From June 2001 to help November 2006, after on the list of achieved clinical response with first-line chemotherapy, patients with mCRC within our hospital received two different treatment strategies. Thirty-three patients non-maintenance group don't receive any further chemotherapy. Results: Patients in maintenance group and non-maintenance group each of those received FOLFOX, FOLFIRI and XELOX as first-line treatments. The median chemotherapy cycles the 2 main groups received were this same(6 vs 6). This response rates of first-line chemotherapy were 33. 3% in maintenance group and 32. 7% in non-maintenance group. Patients within maintenance group received 3-9 menstrual cycles of capecitabine therapy(typical cycle 4). 29/33(87. 9%)patients within maintenance group and 47/52(92. 4%)in non-maintenance set received following second-line chemotherapy, no patients underwent targeted therapy. The median survival time period and TTP were forty. 4 months(95%CI: 24. 2-56. 6)and 9. 0 months(95%CI: 6. 7-11. 3)in maintenance group, as compared using 21. 5 months(95%CI: 14. 9-28. 0, P=0. 015)and 6. 5 months(95%CI: 4. 4-8. 5, P=0. 007)in non-maintenance party. No severe adverse event was observed in the capecitabine maintenance set. Conclusion: mCRC patients could benefit from capecitabine maintenance therapy just by prolonging survival time together with TTP. combination of the meds Velcade and belinostat may very well be active in patients using myelodysplastic syndromes, according to outcomes of a small Phase 1 scientific trial. These results were presented during a poster session at this 2011 American Society of Hematology (ASH) meeting last month. Velcade (bortezomib) happens to be approved by the U. S. Food and Drug Administration for the relief multiple myeloma and layer cell lymphoma. Belinostat (PXD 101), which is being developed jointly through the American company Spectrum Pharmaceuticals (NASDAQ: SPPI) along with the Danish company TopoTarget, belongs for a class of drugs known as histone deacetylase (HDAC) inhibitors. HDAC inhibitors work by increasing the manufacturing of proteins that slow cell division and cause cell death. Zolinza (vorinostat), which is also being investigated as a potential treatment for myelodysplastic syndromes (MDS), is one of the same class of drugs as belinostat and contains shown promising results in conjunction with Vidaza (azacitine) within MDS patients with poor health (see related Beacon info). Previous clinical trials demonstrate that treatment with Velcade or belinostat alone is not really effective against MDS. However, proteasome inhibitors such since Velcade and HDAC inhibitors like belinostat have been proven to act synergistically, prompting the researchers to research whether a Velcade-belinostat combination may be effective for patients using blood cancers. The primary goal of this Phase 1 trial was to look for the maximum safe dose with Velcade and belinostat for use in future Phase 2 demos. So far, 13 people with acute myeloid leukemia, chronic myelogenous leukemia, or MDS using a median age of 59 years have signed up for the study. The participants had received a median of two prior remedies. So I was out of the country last week and for when in two years involving maintenance, missed a Velcade infusion. I'm told I'm allowed to do that twice a year and remain on protocol, so no biggie. However, I did notice I did so not have gastroparesis. Thus, my brilliant powers associated with deduction lead me to conclude that it is Velcade, and not Revlimid or even Dex, that is the culprit. This may be of usage the others, hence my own posting it. I possess a checkup with my local onc tomorrow and will post whatever news is actually merited! Pazopanib (GW786034) is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and-3, platelet-derived growth factor receptor-α, platelet-derived growth factor receptor-β, and c-kit. Preclinical evaluation has revealed excellent antiangiogenic together with antitumor activity, and synergism was observed in combination with chemotherapeutic drugs. Significant antitumor activity was found in animal models of several tumors, accompanied by desirable pharmacokinetics and oral bioavailability. Phase I clinical demos have revealed manageable toxicities and desirable pharmacokinetics together with activity in renal cancer and several other tumors. Ongoing trials are further evaluating pazopanib in a variety of malignancies. Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth component receptor, platelet-derived growth component receptor, and c-Kit. The following randomized, double-blind, placebo-controlled phase III study evaluated efficacy and safety of pazopanib monotherapy in treatment-naive and cytokine-pretreated people with advanced renal cell carcinoma (RCC). PEOPLE AND METHODS Adult people with measurable, locally advanced, and/or metastatic RCC were randomly assigned 2: 1 to take delivery of oral pazopanib or placebo. The main end point was progression-free survival (PFS). Secondary end points included overall survival, tumor response charge (Response Evaluation Factors in Solid Tumors), together with safety. Radiographic assessments involving tumors were independently researched. Results Of 435 patients enrolled, 233 were procedure naive (54%) and 202 were cytokine pretreated (46%). PFS was significantly prolonged with pazopanib compared with placebo in the general study population (median, PFS 9. 2 v 4. 2 months; hazard ratio [HR], 0. 46; 95% CI, 0. thirty four to 0. 62; K <. 0001), that treatment-naive subpopulation (typical PFS 11. 1 / 2. 8 months; HR, 0. 40; 95% CI, 0. 29 to 0. 60; P <. 0001), and also the cytokine-pretreated subpopulation (median PFS, 7. 4 v 4. 2 months; HR, 0. 54; 95% CI, 0. 35 to 0. 84; K <. 001). The objective response rate was 30% with pazopanib compared with 3% with placebo (K <. 001). The median duration with response was longer than 12 months. The most common damaging events were diarrhea, hypertension, locks color changes, nausea, anorexia, together with vomiting. There was no evidence of clinically important differences in quality of life for pazopanib versus placebo. CONCLUSION Pazopanib demonstrated vital improvement in PFS and tumor response weighed against placebo in treatment-naive together with cytokine-pretreated patients with advanced and/or metastatic RCC. (Comment on this)
10:30 am	All about Capecitabine, Velcade, Pazopanib inhibitors Capecitabine is an orally administered prodrug of 5-fluorouracil (5-FU). It is currently approved for dealing metastatic breast cancer refractory to help anthracyclines and paclitaxel, together with for first-line treatment of metastatic colorectal cancer. The drug belongs to a new and rapidly expanding class of therapeutics, produced for oral treatment associated with cancer. Oral treatment comes with several advantages over my partner and i. v. treatment, especially in patients with incurable melanoma. It can lead to help prolonged exposure of tumor cells to your antineoplastic effects of anticancer substances, mimicking the more heavy continuous i. v. infusions; it can be more convenient for people, of whom >80% would prefer oral to i. v. treatment; and it may be less expensive, considering fees saved in drug administration An additional advantage, which makes capecitabine Pazopanib,Capecitabine,Velcade an attractive combination, is its assumed concentrating on of tumor tissue. The parent drug is first changed into 5′-deoxy-5-fluorocytidine (5′-DFCR) by way of the enzyme carboxylesterase, which exists predominantly in the liver. 5′-DFCR is then converted to 5′-deoxy-5-fluorouridine (5′-DFUR) through the enzyme cytidine deaminase, which is more widely distributed like the liver and various cancer tissues. Finally, 5′-DFUR is converted to 5-FU by thymidine phosphorylase (TP). TP is identical to your angiogenic agent ‘platelet produced endothelial cell growth factor’ (PD-ECGF). Expression of TP is actually increased in tumor tissue compared with normal tissue. The proposed accumulation involving 5-FU in tumors by metabolic targeting has been confirmed by measurement of 5-FU concentrations in colorectal cancer tissue weighed against adjacent normal tissue. Targeting of tumor tissue by capecitabine may result in a favorable balance of procedure efficacy and toxicity. Cardiotoxicity, a rare but potentially significant toxicity of fluoropyrimidines, has not been reported for capecitabine to date. Here we report someone without evidence of cardiomyopathy or coronary heart disease, who developed heart ischemia with severe angina after oral administration of capecitabine. This observation suggests the necessity for caution when treating patients considered susceptible to fluoropyrimidine-associated cardiac toxicity. To evaluate the efficacy and toxicity involving capecitabine maintenance therapy in metastatic colorectal cancer(mCRC)patients. Solutions: From June 2001 to help November 2006, after they had achieved clinical response from first-line chemotherapy, patients with mCRC within our hospital received two different treatment strategies. Thirty-three patients non-maintenance group didn't receive any further chemotherapy. Results: Patients in maintenance set and non-maintenance group each of those received FOLFOX, FOLFIRI together with XELOX as first-line therapy. The median chemotherapy cycles the 2 main groups received were the same(6 vs 6). The response rates of first-line chemotherapy were 33. 3% in maintenance group and 32. 7% within non-maintenance group. Patients within maintenance group received 3-9 fertility cycles of capecitabine therapy(typical cycle 4). 29/33(87. 9%)patients within maintenance group and 47/52(92. 4%)in non-maintenance set received following second-line chemotherapy, with zero patients underwent targeted therapy. The median survival time period and TTP were 40. 4 months(95%CI: 26. 2-56. 6)and 9. 0 months(95%CI: 6. 7-11. 3)in repair group, as compared using 21. 5 months(95%CI: 16. 9-28. 0, P=0. 015)and 6. 5 months(95%CI: 4. 4-8. 5, P=0. 007)in non-maintenance set. No severe adverse event was observed in the capecitabine maintenance group. Conclusion: mCRC patients could profit by capecitabine maintenance therapy as a result of prolonging survival time and TTP. combination of the drug treatments Velcade and belinostat may very well be active in patients with myelodysplastic syndromes, according to results of a small Phase 1 scientific trial. These results were presented within a poster session at that 2011 American Society with Hematology (ASH) getting together with last month. Velcade (bortezomib) is currently approved by the U. S. Food and Drug Administration for dealing with multiple myeloma and mantle cell lymphoma. Belinostat (PXD info), which is being developed jointly by way of the American company Spectrum Pharmaceutical drugs (NASDAQ: SPPI) and the Danish company TopoTarget, belongs to your class of drugs termed histone deacetylase (HDAC) inhibitors. HDAC inhibitors operate by increasing the production of proteins that impede cell division and cause cell death. Zolinza (vorinostat), that's also being investigated as a potential treatment for myelodysplastic syndromes (MDS), belongs to the same class of drugs as belinostat and has shown promising results in combination with Vidaza (azacitine) within MDS patients with poor health (see related Beacon news). Previous clinical trials have shown that treatment with Velcade or belinostat alone is not effective against MDS. Nevertheless, proteasome inhibitors such since Velcade and HDAC inhibitors which include belinostat have been shown to act synergistically, prompting the researchers to research whether a Velcade-belinostat combination may be effective for patients with blood cancers. The primary goal from this Phase 1 trial was to determine the maximum safe dose of Velcade and belinostat for used future Phase 2 demos. So far, 13 people with acute myeloid leukemia, serious myelogenous leukemia, or MDS which has a median age of 59 years have signed up for the study. The members had received a median of two prior remedies. So I was out of your country last week and for the first time in two years associated with maintenance, missed a Velcade infusion. I'm told I'm allowed to achieve that twice a year and stick to protocol, so no biggie. However, I did notice I did so not have gastroparesis. Thus, my brilliant powers with deduction lead me to conclude that it is Velcade, and not Revlimid or even Dex, that is the culprit. This may be of use the others, hence my own posting it. I have a checkup with my local onc tomorrow and will post whatever news is actually merited! Pazopanib (GW786034) can be a second-generation multitargeted tyrosine kinase inhibitor next to vascular endothelial growth component receptor-1, -2, and-3, platelet-derived growth factor receptor-α, platelet-derived growth factor receptor-β, and c-kit. Preclinical assessment has revealed excellent antiangiogenic and antitumor activity, and synergism was observed in conjunction with chemotherapeutic drugs. Significant antitumor activity was found in animal models of various tumors, accompanied by pleasing pharmacokinetics and oral bioavailability. Phase I clinical trials have revealed manageable toxicities and desirable pharmacokinetics together with activity in renal cancer and a few other tumors. Ongoing trials are further evaluating pazopanib in a number of malignancies. Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth component receptor, platelet-derived growth factor receptor, and c-Kit. The following randomized, double-blind, placebo-controlled stage III study evaluated efficacy and safety of pazopanib monotherapy within treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). PATIENTS AND METHODS Adult people with measurable, locally sophisticated, and/or metastatic RCC were randomly assigned 2: 1 to take delivery of oral pazopanib or placebo. The primary end point was progression-free tactical (PFS). Secondary end points included over-all survival, tumor response charge (Response Evaluation Requirements in Solid Tumors), together with safety. Radiographic assessments with tumors were independently reviewed. Results Of 435 patients enrolled, 233 were treatment naive (54%) and 202 were cytokine pretreated (46%). PFS was significantly prolonged with pazopanib compared with placebo in the general study population (median, PFS 9. 2 / 4. 2 months; hazard ratio [HR], 0. forty six; 95% CI, 0. 34 to 0. 62; P <. 0001), that treatment-naive subpopulation (median PFS 11. 1 / 2. 8 months; HR, 0. 40; 95% CI, 0. 29 to 0. 60; P <. 0001), along with the cytokine-pretreated subpopulation (median PFS, 7. 4 / 4. 2 months; HR, 0. 54; 95% CI, 0. 35 to 0. 84; P <. 001). The target response rate was 30% with pazopanib compared with 3% with placebo (P <. 001). The median duration of response was longer than 12 months. The most common adverse events were diarrhea, hypertension, locks color changes, nausea, anorexia, together with vomiting. There was no evidence of clinically important differences in standard of living for pazopanib versus placebo. CONCLUSION Pazopanib demonstrated significant improvement in PFS and tumor response weighed against placebo in treatment-naive and cytokine-pretreated patients with sophisticated and/or metastatic RCC. (Comment on this)
Monday, February 20th, 2012
12:17 pm	All about Capecitabine, Velcade, Pazopanib inhibitors Cancerous tumors are seen as a cell division, which is not a longer controlled as it's in normal tissue. "Normal" skin cells stop dividing when they touch like cells, a mechanism known as contact inhibition. Cancerous skin cells lose this ability. Cancer cells don't have the normal checks and balances in place that control and restrict cell division. The procedure of cell division, whether typical or cancerous cells, is with the cell cycle. This cell cycle goes in the resting phase, through active growing phases, and next to mitosis (department). The capability of chemotherapy to kill cancer cells will depend on its ability to halt cell division. Usually, the drugs work as a result of damaging the RNA and DNA that tells the cell how to copy itself in division. If the cells are unable to divide, these people die. Your faster the cells are dividing, the more likely it can be that chemotherapy will eliminate the cells, causing that tumor to shrink. Additionally they induce cell suicide (self-death and apoptosis). Chemotherapy drug treatments that affect cells only when they are dividing are called cell-cycle specific. Chemotherapy drugs that affect cells when they are at rest are generally called cell-cycle non-specific. That scheduling of chemotherapy is set based on the type of cells, rate when they divide, and the time at which a given drug may be effective. That is why chemotherapy is normally given in cycles. Chemotherapy is more effective at killing cells that are rapidly dividing. Unfortunately, chemotherapy fails to know the difference relating to the cancerous cells and the standard cells. That "normal" cells will grow back and become healthy but in the meantime, adverse reactions occur. The "normal" cells most commonly affected by chemotherapy could be the blood cells, the cells inside mouth, stomach and bowel, and the hair hair follicles; resulting in low circulation counts, butt end sores, nausea, diarrhea, and/or hair loss. Different drugs may affect different parts of the body. Capecitabine Velcade inhibition, Capecitabine inhibitor, Pazopanib inhibition belongs to the category of chemotherapy called antimetabolites. Antimetabolites are very similar to normal substances within your cell. When the cells incorporate these substances in the cellular metabolism, they are unable to divide. Antimetabolites are cell-cycle specific. They attack cells at very specific phases in the cycle. Antimetabolites are classified using the substances with which people interfere. VELCADE is co-developed as a result of Millennium and Ortho Biotech Oncology Explore & Development, a product of Johnson & Johnson Pharmaceutical Research & Advancement, L. L. J. Millennium is in charge of commercialization of VELCADE in the U. S., Janssen-Cilag is responsible for commercialization in Europe and all of those other world. Takeda Pharmaceutical Company Limited and Janssen Prescription drug K. K. entered to a co-promote agreement in May 2010 for VELCADE with Japan. VELCADE is approved in more than 90 countries and has been used to treat a lot more than 230, 000 patients around the globe. The study showed that will consolidation with VELCADE produced significant improvements in answer rates and progression-free tactical, while the overall survival rate was 87 percent in both arms after having a median follow-up of 27 months. These kind of data were presented at the 13th International Myeloma Workshop, held May 3-6 with Paris, People from france. The improvements in progress free survival with VELCADE consolidation add to the demonstrated overall survival benefit from VELCADE induction and maintenance previously reported at ASH 2010 through the HOVON group, Results of the PALETTE (PAzopanib Researched in SofT-Tissue Sarcoma) study presented in the 2011 Annual Meeting of the American Society for Clinical Oncology demonstrated a statistically significant improvement inside time to first prevalence of tumour progression and also death (progression absolutely free survival or PFS) with regard to study patients treated while using the multi-tyrosine kinase inhibitor pazopanib, as compared to placebo. PALETTE is a randomised, double-blind, placebo controlled Phase III trial in patients with metastatic soft tissue sarcomas (excluding gastrointestinal stromal tumours and adipocytic sarcomas) together with was jointly conducted by GlaxoSmithKline and also the European Organisation for Exploration and Treatment of Tumor (EORTC) in collaboration with cancer centres many countries. Use of pazopanib to treat soft tissue sarcomas is investigational and controlled by evaluation of benefits together with risks by regulatory authorities before being produced for that use. 369 adults with positive metastatic soft tissue sarcomas in whose disease had progressed irrespective of treatment with chemotherapy were randomly assigned on the 2 to 1 basis to pazopanib or placebo. Once we known, pazopanib (GW786034) can be a substrate of CYP3A4 the industry P-plycoprotein and breast cancer resistence protein. Pazopanib (GW786034) weakly stops CYP3A4 and CYP2C8, as well as CYP2D6. However, pazopanib (GW786034) potently blocks those activities of UGT1A1 and OATP1B1. Due to the metabolism of pazopanib(GW786034) by way of the liver metabolic enzyme CYP3A4, concurrent inhibitors and inducers in the activities of the metabolic enzyme CYP3A4 may influence the metabolism involving pazopanib (GW786034). (Comment on this)
Wednesday, February 15th, 2012
8:02 pm	All about Capecitabine, Velcade, Pazopanib inhibitors A 1700-year-old Chinese herbal medicine known in the medical literature as PHY-906 may be researched in over 20 scientific studies as a treatment with regard to pancreatic cancer. It actually generally seems to work.Velcade inhibition,Capecitabine inhibition,Pazopanib PHY-906 is a combination of four herbs that are traditionally useful to treat nausea and diarrhea. The herbs are scutellaria, licorice, jujube, together with peony. As you probably guessed, traditional Chinese medicine does not refer to this combination as PHY-906. It's more commonly called Huangquin Tang. Phytoceutica, a pharmaceutical firm in New Haven, Connecticut, and the school of Pharmacy at Yale developed a protocol for uncovering the purity and shelf-stability associated with patent medicines from China made out of these four herbs, and found considerable difference inside potency of products from different companies. Phytoceutica then developed a process for making the herbs within a reliable potency with some sort of pharmaceutical carrier, to make sure they get where they need to go in the digestive system, which it patented. This Chinese herbal medicine isn't that will treat pancreatic cancer independently. It's designed to help make doxorubicin, thalidomide, capecitabine, gemcitabine, and oxaliplatin more bearable and so the the chemotherapy can do your work for fighting that cancer. There's no doubt you may go to any general practitioner of Traditional Chinese Medicine and get the four herbs, probably in a form you must "boil up" into some sort of tea (although these particular herbs work better once they aren't actually boiled, but instead steeped in hot water in a covered tea pot). To put it in the terms usually as used by alternative medicine gurus, these herbs are a "detox" for chemo, that doesn't restrict its anti-cancer action. Don't do that own your own. There aren't likely to be any bad interactions with anti-cancer drugs, but the licorice may well react with drugs your physician gives you for excessive blood pressure, or using steroids. But do inquire if a state-licensed practitioner of Traditional Chinese Medicine can figure with your oncologist to use the herbs to guide control the nausea and diarrhea brought on by chemo. Beating the passing sentence from Multiple Myeloma Cancer Before a couple of in years past, when someone was diagnosed with having multiple myeloma, a bone marrow cancer, they were basically given a death sentence that would happen within two years at the outside. I'm here to tell you that it can be beat! I have had first-hand experience watching my cousin receiving that diagnosis in February of 2008.... three years ago this month. I want to give some encouragement to anyone who has been diagnosed with this deadly cancer with the plasma cells. Some with the symptoms associated with the following cancer include: Bleeding problems - Cuboid bone or back pain (most often in the ribs or back) - Fevers which has no other cause -increased susceptibility to help infection - Symptoms of anemia (which include tiredness, shortness of breath, and fatigue) - Unexplained fractures - Weakness of the arms or legs My cousin fell off a ladder and landed on their back, so he seen tremendous back pain. He thought he could shake it off, but after a couple weeks, he was convinced to travel to his primary care physician. He recommended that my cousin see a specialist... Dr. Stephen Mayer - that practices oncology and intrinsic medicine in Brockton, Boston. I wanted to allow this doctor's name because he saved my brother's life... and surprised himself along the way. A new medication - Revlimid, was recommended as the proper treatment in my own brother's case. It was new, FDA approved with 2005. Here is what Mayo Clinic is reporting as treatment (nevertheless) for multiple myeloma: "Chemotherapy and bone marrow transplant will be the primary options. " "Thalidomide is used along with dexamethasone to help remedy multiple myeloma in individuals who been recently found to have this disease. " Doctor. Mayer, however, recommended Revlimid... a seven-month treatment, and the price tag on the pills for a month ran $6, 800. Nobody can afford to pay $6, 800 a month for medicine, but my brother was very fortunate since his insurance actually paid for most of it, and the maker of Revlimid improved out, too. Now, I am not in the professional medical profession, but I can allow this first-hand, eyewitness account in the ordeal. My brother was severely ill out of this disease and medication. One day, when I brought him to Dr. Mayer's company, he was so weak and sick that they knelt down in your bushes and threw up for what seemed once and for all. He could barely gather enough strength to get inside for the meeting, and this went on for a couple of months. At some issue, I can't remember just when, my brother heard this from Dr. Mayer, " We don't generally say the following, but you seem to be in remission. " That news seemed to be the mental boost that my brother needed to move him forward psychologically. When they first met, the superior doctor said, "Y ou may get two months or a couple of years, I have no way to know. " That's three years ago... but, I have more good news. As time went on, my brother decided to work with the VA because he would not be capable to afford a lot of the medications and treatments, and he or she is a Viet-Nam veteran. This VA took him, and wanted to prescribe the Thalidomide, but my brother instructed them how he was responding well to the Revlimid. The cost was a huge component, but the VA finally said they will order the Revlimid, and let my brother finish the course with them. As it turned out, my brother would attempt to also get a cuboid bone marrow transplant in Nashville in the VA hospital there. It was tough, but he gained through it just okay. When he first went for testing, his cancer cells were 50% of his bone marrow. Prior to the VA would do that transplant, they needed to find his counts at or below 20%, and right after they finished the transplant, they expected a 5% cancer cellular count - but my brother came away from your VA with zero cancer cells within his bone marrow. After his release in the hospital, my brother had to wear morphine patches called Fentanyl, and that treatment would probably manage the pain in the deterioration of the bone tissues. Over time, he went to the local VA for what they call Zometa... some sort of liquid treatment that by some means strengthens the damage done by the cancer to the bones. He began to slowly wean heli-copter flight Fentanyl patches to where he doesn't use them anymore, and hasn't for about a year. His appointments would be every little while, then months... and finally, he was told that they didn't have to profit for major exams to get a year. My brother had been issued a death sentence in 1990 when he contracted throat cancer - from smoking, of course. He was told that he might make it to April of 1990. It's twenty-one years later, together with he's still here... happy and living life, so I just wished to encourage anyone with cancer that the first thing you decide to do is fight. My brother never quit. He might always tough it out, and had the attitude that they could beat this condition - this killer called cancer, and has executed so twice now. People cannot discount prayer. Lots of prayers went up to heaven from his friends and family, and from his own lips, and God must have heard them all since He let him live through the 23. 5 years of cancer. NOW CAN COME THE CAUTION: PLEASE LISTEN TO THIS.... About three a long time ago, my brother, Verne, began to lose his appetite. He thought it was eventually strange, but paid that no mind. He decided on the VA for their checkup, and they produced a bone scan, nevertheless found nothing of issue. Days and weeks went by, and Verne began to have the old bone pain that he used to feel when the cancer was first identified... but he wrote it off to doing an excessive amount lifting. After two a few months had passed, Verne had no appetite and began to lose weight. On January 21, 2011, he went to the hospital and that they ran a blood test on him. His CALCIUM levels were high. They should be 8... they were 16. This was the first and only sign that the myeloma was back . On February 23rd, he was released from the VA, nevertheless - before he became home, they called him back for the reason that thought he had contracted pneumonia - according to another test they had run. He did have pneumonia, so they publicly stated him One week elapsed in the time Verne was admitted on February 23rd... some sort of Wednesday... to the next Wednesday.... at 3PM... he left for be with the Head of the family. Now, here is the message that Verne wish to give to fellow myeloma people: When you go in for your tests.... HAVE ALWAYS THEM CHECK YOUR CALCIUM LEVELS . He could have made it, had he gone set for the calcium check any time he first had symptoms of fatigue, loss associated with appetite, bone pain (again and ribs), and they could have put him on VELCADE... the newest, more potent drug. By the time Verne admitted to everyone that he was in a great deal of pain... it was 3 months too late really to save him. His immune system was shot. His cuboid bone marrow contained over 80% cancer plasma cells. They got his calcium count down to a comfortable 9. 0, consequently his prognosis was good. His oncologist said he or she could begin the VELCADE solutions. The only problem was - his defense mechanisms was shot, so he acquired the pneumonia - which have been causing his demise in one short week. If that were me.... I would have my blood checked monthly for calcium levels. One can go through another treatment of Revlimid or now Velcade... and make the idea, but don't be unreasonable. When pain strikes... and appetite loss hits, and weight declines... get in and have the calcium levels checked because myeloma WILL COME BACK.... and with a vengeance in the event you ignore the symptoms together with signs that only YOU, the patient, can know and feel. There have been so many technical and medical breakthroughs is cancer research together with medicines - especially this Revlimid and/or Velcade treatments that were not available even a few years ago, so keep the faith... talk to your physicians, and don't stop trying. Do not ever give up. Verne might have caused it to be had he just taken notice of the signs and knew enough to ask for the calcium level check ups. (Comment on this)